Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Interfant-21 (ALL)

Clinical study for infants with acute lymphoblastic leukemia with a KMT2A gene rearrangment
Who can enter
  • Children with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangment
  • Age < 1 year at diagnosis


The goal of this study is to improve outcome compared with historical results of the former Interfant trial (Interfant-06) in infants with KMT2A rearranged ALL.


Children < 1 year of age with acute lymphocytic leukemia (ALL) with a KMT2A gene rearrangement have a poor prognosis. These children need innovative and new therapeutic agents to improve the outcome.

Infants are routinely treated according to the Interfant-21 protocol. The difference with the former protocol (Interfant-06) is that blinatumomab, an immunotherapy, has been added as standard to chemotherapy treatment. Blinatumomab has far fewer side effects than chemotherapy and the results from a small study with this drug are very promising.

In Interfant-21, disease and treatment data will be collected in a database to gain insight into the effect and side effects of the medicines used in this treatment protocol. Body material (blood, bone marrow and liquor) will also be used for research.

The research in the Interfant-21 protocol consists of several parts.
There are three general parts:

  1. Collection of data on disease, treatment and outcomes in a database
  2. Storage of body material ("residual material"): blood, bone marrow and cerebrospinal fluid (CSF)
  3. Treatment with blinatumomab

In addition, there are a number of sub-studies, for which participants can decide for each component whether or not they want to participate:


In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Office

Last reviewed

May 17, 2023